Menu
Menu
Translating NGS Workflows into Real-World Impact in Hemato-Oncology
You are invited to join our networking event on hematologic malignancies during the 2025 Association of Molecular Pathologists Annual Meeting & Expo in Boston, USA.
Connect with peers and leading experts to explore how NGS-based solutions are advancing the investigation of complex variants in hematological malignancies.
During this event, speakers from renowned institutions will share real-world experiences implementing diverse NGS applications, including:
This is your opportunity to learn how peers are overcoming technical hurdles, realizing practical benefits, and applying NGS strategies to make genomic interpretation and decision-making in blood cancers more efficient.
What: Blood Cancer Showcase at AMP
Where: Omni Hotel - Marquee Room
Date: November 12th
Time: 6:30 pm – 8:15pm
Agenda to follow
Reserve your seat to this exclusive event on Wednesday, November 12th starting at 6:30 pm.
SALT LAKE CITY AND BOSTON, MA - September 23, 2025 – Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad’s advanced laboratory capabilities in the U.S. to support global testing for clinical trials and SOPHiA GENETICS’ broad, decentralized network of more than 800 connected institutions in more than 70 countries for global test deployment.
“Serving patients and healthcare providers along the cancer care continuum is a strategic focus for Myriad Genetics,” said Sam Raha, President and CEO, Myriad Genetics. "We expect this collaboration with SOPHiA GENETICS to support the development and global commercialization of comprehensive CDx solutions for our BioPharma partners with the potential to positively impact patient lives, add an important product offering to the Myriad menu and support the growth of our CDx programs."
SOPHiA GENETICS and Myriad will initially focus on the liquid biopsy application, MSK-ACCESS® powered with SOPHiA DDM™. Developed in collaboration with Memorial Sloan Kettering Cancer Center, MSK-ACCESS® powered with SOPHiA DDM™ is an innovative liquid biopsy test that detects actionable genomic alterations from a single blood draw using proprietary, state-of-the-art algorithms which analyze circulating tumor DNA (ctDNA). By developing the application into a CDx, more patients can gain access to the benefits of this high-quality tumor profiling test, advancing personalized healthcare at scale.
Myriad will pursue regulatory submissions in the U.S., and SOPHiA GENETICS will manage regulatory submissions outside of the U.S. Both companies will collaborate across development activities. This innovative, hybrid approach is expected to provide pharmaceutical partners with access to key regulated markets globally.
“This collaboration represents a pivotal moment for the industry,” said Jurgi Camblong, Co-founder and CEO of SOPHiA GENETICS. “By combining the complementary strengths of a specialty lab leader and a global testing network, we are not only expanding access to innovative oncology testing but also laying the foundation for a new hybrid model in companion diagnostics. This collaboration will allow us to serve both clinical and pharmaceutical partners better, while accelerating the adoption of liquid biopsy solutions across key markets.”
SOPHiA GENETICS and Myriad will participate in a panel discussion at the World CB and CDx Summit in Boston and provide additional details on the collaboration.
SOPHiA GENETICS is thrilled to return and join the genomics community at this year’s American Society of Human Genetics (ASHG) Annual Meeting in Boston, Massachusetts.
Visit Booth #1040 to explore the next-generation SOPHiA DDM™ Platform and Alamut™ Visual Plus, and uncover our latest advancements in Enhanced Exome and Whole Genome Sequencing analytics.
Join us and be part of the conversation with our experts, partners, and users as we tackle the challenges of rare and inherited disorder and pharmacogenomic analysis.
Poster Presentation
Wednesday, Oct 15 | 02:30 – 04:30 PM | Exhibit & Poster Hall, Lower Level Board 8008W
Authored and presented by: Adrian Janiszewski
Co-lab Theater Talk
Thursday, Oct 16 | 12:00 – 12:30 pm | Theatre 1, Exhibit & Poster Hall, Lower Level
Simple workflows for complex genomics: A closer look at our latest enhanced exome and whole genome capabilities
Presented by: Guilherme Yamamoto, Head of Genomics and Bioinformatics Innovation, Dasa Brazil
Presented by: Izabela Matyszczak, Technical Product Management Expert, Genomic Research Expert, SOPHiA GENETICS
SOPHiA GENETICS is excited to join this year’s International Society of Liquid Biopsy (ISLB), in Orlando, Florida, where we’ll showcase our latest liquid biopsy applications designed to advance oncology research and tumor mutation profiling.
Visit us at Booth #302 to connect with our team and explore innovative solutions, including MSK-ACCESS® powered with SOPHiA DDM™, to see how we’re helping shape the future of precision medicine.
Showcase Theatre
Sunday, Nov 2 | 10:50 – 11:10 AM | Showcase Theatre
Decentralized Liquid Biopsy Testing Using MSK-ACCESS® with SOPHiA DDM™: Insights from Multi-Cancer Clinical Profiling in OncoHelix
Presented by: Dr. Rehan Mujeeb Faridi, Director of Molecular Diagnostics, OncoHelix
SOPHiA GENETICS is excited to attend this year’s Association of Molecular Pathology (AMP) Annual Meeting!
Find us at booth #921 to learn about how we are enabling breakthrough innovations in cancer research.
Wednesday, November 12, 10:00 – 10:50 am | Corporate Workshops | 160C Level 1
Elevating CGP with Agile Solutions: The New MSK-IMPACT® Flex powered with SOPHiA DDM™
Speakers:
Wednesday, November 12, 11:00 – 11:50 am | Corporate Workshops | 160C Level 1
Redefining Precision Oncology with MSK-ACCESS® powered with SOPHiA DDM™
Speakers:
Friday, November 14, 9:15am – 10:15am | Poster number: ST044
Robust RNA profiling using the SOPHiA DDM™ RNAtarget Oncology Solution with FFPE tumor samples
Authored by: Izabela Matyszczak, Slawomir Kubik, Jonathan Bieler, Ewan Smith, Jonathan Lopez, Alexandre Harlé, Christian Pozzorini, Zhenyu Xu
Saturday, November 15, 9:15am – 10:15am | Poster number: ST041
MSK-IMPACT Flex powered with SOPHiA DDM™ enables sample-specific comprehensive genomic profiling through selective analysis of DNA and RNA biomarkers
Authored by: Izabela Matyszczak, Christian Pozzorini, Gregoire André, Tommaso Coletta, Amjad Alkodsi, Frederic Michaud, Yvan Wenger, Elia Magrinelli, Anjali Anjali, Zhenyu Xu
We are thrilled to be back at 15th World Clinical Biomarkers & Companion Diagnostics Summit. Join us and meet our BioPharma team to learn how we help BioPharma companies address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
If you are attending, don’t miss:
Lunch & Learn hosted by SOPHiA GENETICS on Wednesday, September 24th, from 1.10 to 2.10 pm.
Join us for a special lunch session spotlighting the journey of MSK-ACCESS® powered with SOPHiA DDM™ from an in-house solution at Memorial Sloan Kettering Cancer Center (MSK) to a globally scalable, decentralized, best-in-class liquid biopsy platform, through a strategic collaboration with SOPHiA GENETICS.
Talk on Thursday, September 25th, from 11.00 to 11.30 am, in Track A.
“Bridging the Gap: A Hybrid Deployment Model for Scaling Innovation in Oncology”
Jess Lambe, Vice President and Managing Director of BioPharma Business Development, SOPHiA GENETICS
We are glad to be at BioTechX USA 2025, where you will have the chance to meet our BioPharma team for two days of exciting networking, innovation, and insights sharing on the potential of AI-driven solutions to transform precision medicine.
If you are around, don’t miss our talk on September 17th from 12.05 to 12.25 PM, in the AI in Drug Development and Discovery track, for an insightful talk about how SOPHiA GENETICS is building a world where clinicians make faster, more informed decisions, and every patient contributes to a smarter and more equitable future in medicine.
“Unlocking the Power of Data: AI-Driven Insights for Precision Medicine”
Kellen Sanger, Head of Strategy and Programs, SOPHiA GENETICS
You’ll get to explore howAI and collective intelligence are translating vast amounts of data into actionable insights, enabling clinicians to make more informed decisions and improving outcomes across borders.
We are excited to be at the 24th Annual Bio-IT World Conference & Expo. Join us at booth #724 and meet our BioPharma and Multimodal R&D experts to learn how we help BioPharma companies address challenges throughout the drug development continuum with data solutions tailored to their needs, bringing more effective drugs to the right patients.
If you are attending, don’t miss our talk on Friday, April 4th from 12.10 to 12.40pm, in the AI for Oncology, Precision Medicine & Health track.
“SOPHiA DDM™ for Multimodal: Advancing Precision Oncology with AI-Driven Analytics”
Paul Bernard, Data Engineer, Multimodal R&D, SOPHiA GENETICS
Join this session to explore how SOPHiA DDM™ for Multimodal is shaping the future of cancer care, one breakthrough at a time:
SOPHiA GENETICS is thrilled to be back at ASCO 2025! Meet our experts at booth #32131 to hear about our biopharma solutions. Learn how we are leveraging our unique AI expertise, to provide an unparalleled offering, unlocking insights from complex data types, driving faster discovery of new stratifying biomarkers, in addition to aiding in the commercialization of precision medicines
SOPHiA GENETICS is thrilled to be back at AACR 2025! Visit us at booth #2856 to learn how we advance data-driven medicine, with our cloud-based SOPHiA DDM™ Platform. Discover how it empowers health data interpretation with advanced analytics modules, simplified reporting, and a global community of healthcare institutions. By harnessing the power of AI and multimodal data-driven analytics, we enable you to advance and streamline global access to precision therapies.
Decentralized pan-cancer tumor profiling: A comprehensive performance evaluation of the MSK-IMPACT® Assay with SOPHiA DDM™
Presented by
Julien Pontis, PhD - Technical Product Manager and Lead Data Scientist, SOPHiA GENETICS
Fuad Mohammad, PhD - Senior Bioinformatican, Bioinformatics Product Development, SOPHiA GENETICS
Sunday, April 27 | 2 PM – 5 PM
Poster Board Number: 24
Real-World Insights into the Accuracy and Precision of the Decentralized MSK-ACCESS powered with SOPHiA DDM Solution
Presented by
Florian Klemm, MD, PhD - Technical Product Management Expert, Genomic Research , SOPHiA GENETICS
Monday, April 28 | 9 AM – 12 PM
Poster Board Number: 16
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.